OACC
Oaktree Acquisition Corp. III Life SciencesNASDAQFinancial Services$10.56+0.00%OpenMarket Cap: $259.6M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
35.62
PEG
—
P/B
1.33
P/S
0.00
EV/EBITDA
284.36
DCF Value
—
FCF Yield
-0.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
3.8%
ROA
3.6%
ROIC
-0.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $1.8M | $0.07 |
| FY 2025 | $0.00 | $7.3M | $0.30 |
| Q3 2025 | $0.00 | $2.0M | $0.08 |
| Q2 2025 | $0.00 | $1.9M | $0.08 |
Trading Activity
Insider Trades
View AllMartinez George Arthur
SellWed Oct 29
BERRY DAVID A
SellWed Oct 22
Sweeney Thomas
SellMon Jun 16
Oaktree Acquisition Holdings III LS, LLC10 percent owner
SellThu Oct 31
Oaktree Acquisition Holdings III LS, LLC10 percent owner
SellThu Oct 31
Company Info
Sector
Financial Services
Industry
—
Country
US
Exchange
NASDAQ
Beta
-0.10
Oaktree Acquisition Corp. III Life Sciences focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to acquire companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was incorporated in 2024 and is based in Los Angeles, California.